Genmab A/S

CPSE:GMAB Lagerbericht

Marktkapitalisierung: DKK 105.8b

Genmab Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Genmab verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 18%, während die Gewinne der Branche Biotechs jährlich um gewachsen und zwar um 17%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 23.6%. Die Eigenkapitalrendite von Genmab beträgt 14.4% und die Nettomargen betragen 21%.

Wichtige Informationen

18.05%

Wachstumsrate der Gewinne

19.10%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie18.72%
Wachstumsrate der Einnahmen23.62%
Eigenkapitalrendite14.45%
Netto-Marge21.05%
Nächste Ertragsaktualisierung06 Aug 2026

Jüngste Aktualisierungen vergangener Leistungen

Analyseartikel • May 15

There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...

Recent updates

Analyseartikel • May 15

There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...
Analyseartikel • May 11

Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
Narrativ-Update • Apr 29

GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook

Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
Narrativ-Update • Apr 15

GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook

Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.
Narrativ-Update • Mar 31

GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile

Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.
Narrativ-Update • Mar 17

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
Narrativ-Update • Mar 03

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
Narrativ-Update • Feb 17

GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook

Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.
Narrativ-Update • Feb 02

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
Narrativ-Update • Jan 19

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
Narrativ-Update • Jan 05

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
Narrativ-Update • Dec 14

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
Narrativ-Update • Nov 29

GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook

Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.
Narrativ-Update • Nov 15

GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance

Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.
Narrativ-Update • Nov 01

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain

Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.
Narrativ-Update • Oct 18

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.
Narrativ-Update • Oct 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.
Analyseartikel • Sep 24

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Narrativ-Update • Sep 04

Pipeline Progress And International Expansion Will Unlock Market Opportunities

Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.
Analyseartikel • Jul 31

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
User avatar
Neues Narrativ • Nov 11

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

Aufschlüsselung der Einnahmen und Ausgaben

Wie Genmab Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CPSE:GMAB Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 263,9018216661,687
31 Dec 253,7209636261,606
30 Sep 253,8461,5836431,567
30 Jun 253,6471,3716241,550
31 Mar 253,2331,1365501,438
31 Dec 243,1211,1335491,414
30 Sep 242,9647025191,349
30 Jun 242,7437985011,276
31 Mar 242,5767915041,187
01 Jan 242,3906314781,107
30 Sep 232,3895904661,033
30 Jun 232,378680453979
31 Mar 232,216757422890
31 Dec 222,088785385801
30 Sep 221,580745299688
30 Jun 221,438558268683
31 Mar 221,342354228667
31 Dec 211,288452196640
30 Sep 211,232448156590
30 Jun 211,168401134541
31 Mar 211,703880119512
31 Dec 201,660781108515
30 Sep 201,73688986453
30 Jun 201,55985373417
31 Mar 2083734956378
31 Dec 1980632551358
30 Sep 1953222342317
30 Jun 1948717839291
31 Mar 1944120236250
31 Dec 1846422633220
30 Sep 1843722230191
30 Jun 1839719428174
31 Mar 1846221326164
31 Dec 1738117824137
30 Sep 1736118421126
30 Jun 1735620819110
31 Mar 1727217416101
31 Dec 162571681494
30 Sep 162211111597
30 Jun 162051021490
31 Mar 16183821481
31 Dec 151651111371
30 Sep 15116661466
30 Jun 15115691466

Qualität der Erträge: GMAB hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: GMABDie aktuellen Gewinnspannen (21%) sind niedriger als im letzten Jahr (35.1%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: GMABIn den letzten 5 Jahren sind die Gewinne von 18% jährlich gestiegen.

Beschleunigtes Wachstum: GMABDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: GMAB hatte im vergangenen Jahr ein negatives Gewinnwachstum (-27.7%), was einen Vergleich mit dem Branchendurchschnitt Biotechs (45%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: GMABDie Eigenkapitalrendite des Unternehmens (14.4%) wird als niedrig angesehen.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 14:19
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Genmab A/S wird von 41 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays